◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Colgate-Palmolive (India) Limited (COLPAL) Net Income 2023–TTM

Name: Colgate-Palmolive (India) Limited (COLPAL) net income history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Colgate-Palmolive (India) Limited annual net income for fiscal TTM was ₹13.6 billion, an increase of 2.8% from ₹13.3 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

COLPAL Annual Net Income

Net Income (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	₹13.6B	₹13.3B	₹14.4B	₹13.2B	₹10.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

COLPAL Quarterly Net Income

Net Income (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	₹3.4B	₹3.4B	₹3.5B	₹3.2B	—	₹3.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4527 Net Income — Rohto Pharmaceutical Co.,Ltd.
4967 Net Income — Kobayashi Pharmaceutical Co., Ltd.
4912 Net Income — Lion Corporation
CUPID Net Income — Cupid Limited
8283 Net Income — Paltac Corporation
4922 Net Income — KOSE Holdings Corporation

More COLPAL metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All COLPAL financial statements → Interactive COLPAL charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.